IS2662B - Mótefni sem blokka prótínið Cripto og notkun þeirra - Google Patents
Mótefni sem blokka prótínið Cripto og notkun þeirraInfo
- Publication number
- IS2662B IS2662B IS6999A IS6999A IS2662B IS 2662 B IS2662 B IS 2662B IS 6999 A IS6999 A IS 6999A IS 6999 A IS6999 A IS 6999A IS 2662 B IS2662 B IS 2662B
- Authority
- IS
- Iceland
- Prior art keywords
- antibodies
- block
- cripto protein
- cripto
- protein
- Prior art date
Links
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28678201P | 2001-04-26 | 2001-04-26 | |
| US29302001P | 2001-05-17 | 2001-05-17 | |
| US30109101P | 2001-06-26 | 2001-06-26 | |
| US36700202P | 2002-03-22 | 2002-03-22 | |
| PCT/US2002/011950 WO2002088170A2 (en) | 2001-04-26 | 2002-04-17 | Cripto blocking antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS6999A IS6999A (is) | 2003-10-24 |
| IS2662B true IS2662B (is) | 2010-08-15 |
Family
ID=27501437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS6999A IS2662B (is) | 2001-04-26 | 2003-10-24 | Mótefni sem blokka prótínið Cripto og notkun þeirra |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US7531174B2 (OSRAM) |
| EP (3) | EP1390389B1 (OSRAM) |
| JP (4) | JP4307845B2 (OSRAM) |
| KR (1) | KR100592357B1 (OSRAM) |
| CN (1) | CN100352501C (OSRAM) |
| AR (3) | AR037223A1 (OSRAM) |
| AT (2) | ATE420659T1 (OSRAM) |
| BG (1) | BG108363A (OSRAM) |
| BR (1) | BR0209254A (OSRAM) |
| CA (2) | CA2443840C (OSRAM) |
| CL (1) | CL2009002199A1 (OSRAM) |
| CY (1) | CY1108960T1 (OSRAM) |
| CZ (1) | CZ20033208A3 (OSRAM) |
| DE (1) | DE60230868D1 (OSRAM) |
| DK (1) | DK1390389T3 (OSRAM) |
| EA (1) | EA007469B1 (OSRAM) |
| EE (1) | EE200300528A (OSRAM) |
| ES (1) | ES2321065T3 (OSRAM) |
| GE (1) | GEP20074091B (OSRAM) |
| HU (1) | HUP0501113A3 (OSRAM) |
| IS (1) | IS2662B (OSRAM) |
| MX (1) | MXPA03009797A (OSRAM) |
| MY (2) | MY150237A (OSRAM) |
| NO (1) | NO20034805L (OSRAM) |
| NZ (1) | NZ566268A (OSRAM) |
| PL (1) | PL207087B1 (OSRAM) |
| PT (1) | PT1390389E (OSRAM) |
| RS (2) | RS51635B (OSRAM) |
| SG (1) | SG157951A1 (OSRAM) |
| SI (1) | SI1390389T1 (OSRAM) |
| SK (1) | SK14432003A3 (OSRAM) |
| TR (1) | TR200301846T2 (OSRAM) |
| WO (1) | WO2002088170A2 (OSRAM) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| US20090123470A1 (en) * | 2001-03-26 | 2009-05-14 | The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. | Antibodies Against Cancer |
| US7582299B2 (en) | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| MXPA03009797A (es) | 2001-04-26 | 2004-01-29 | Biogen Inc | ANTICUERPOS PARA BLOQUEO DE PROTEiNA CRIPTO Y USO DE LOS MISMOS. |
| AU2002334799B2 (en) * | 2001-04-26 | 2009-05-07 | Biogen Ma Inc. | Cripto-specific antibodies |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| ATE437950T1 (de) | 2003-09-15 | 2009-08-15 | Res Dev Foundation | Cripto-antagonismus von activin und tgf-b signalisierung |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| AU2007279205B2 (en) * | 2006-07-28 | 2013-09-26 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| JP2010529024A (ja) * | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| JP2011522224A (ja) * | 2008-04-21 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | 膵ベータ細胞質量生物マーカー |
| CA2743057C (en) * | 2008-11-07 | 2019-11-26 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
| US8470980B2 (en) | 2009-09-09 | 2013-06-25 | Centrose, Llc | Extracellular targeted drug conjugates |
| BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
| WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN103313990B (zh) | 2010-11-17 | 2016-07-20 | 基因泰克公司 | 丙氨酰美登醇抗体偶联物 |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| SG11201401406YA (en) | 2011-10-14 | 2014-05-29 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| SMT201800346T1 (it) | 2012-10-12 | 2018-09-13 | Medimmune Ltd | Coniugati pirrolobenzodiazepina-anticorpo |
| PT2906298T (pt) | 2012-10-12 | 2018-12-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpos |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| SI2906253T1 (sl) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EA201691023A1 (ru) | 2013-12-16 | 2016-10-31 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством |
| JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック， インコーポレイテッド | １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
| RU2689388C1 (ru) | 2013-12-16 | 2019-05-28 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами |
| CA2934617A1 (en) | 2013-12-23 | 2015-07-02 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with kinesin spindle protein (ksp) |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック， インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
| MX2017003123A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos y conjugados modificados geneticamente con cisteina. |
| AU2015317653A1 (en) | 2014-09-17 | 2017-04-06 | Genentech, Inc. | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| JP6752204B2 (ja) | 2014-12-03 | 2020-09-09 | ジェネンテック， インコーポレイテッド | 四級アミン化合物及びその抗体−薬物コンジュゲート |
| WO2016161477A1 (en) * | 2015-04-07 | 2016-10-13 | Prince Henry's Institute Of Medical Research (Acn 132 025 024) | A method of treating neoplasias |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ） |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
| EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| ES2871001T3 (es) | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| ES2988683T3 (es) | 2017-06-14 | 2024-11-21 | Adc Therapeutics Sa | Pautas posológicas para la administración de un CAF anti-CD19 |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| KR20220156974A (ko) | 2017-09-20 | 2022-11-28 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CN119405832A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
| EP3894427A1 (en) | 2018-12-10 | 2021-10-20 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| CN113271981B (zh) | 2018-12-13 | 2025-04-11 | 卫材R&D管理有限公司 | 荷伯希二烯抗体-药物缀合物及使用方法 |
| CN119896730A (zh) | 2018-12-17 | 2025-04-29 | 雷维托普有限公司 | 双免疫细胞衔接物 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| EP4637833A2 (en) | 2022-12-23 | 2025-10-29 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| WO2024220546A2 (en) | 2023-04-17 | 2024-10-24 | Peak Bio, Inc. | Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates |
| WO2025132976A1 (en) * | 2023-12-19 | 2025-06-26 | BioNTech SE | Cfc1 binding molecule |
| WO2025132978A1 (en) * | 2023-12-19 | 2025-06-26 | BioNTech SE | Cfc1 binding molecule |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) * | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5780029A (en) | 1989-11-14 | 1998-07-14 | New York Medical College | Antidiotypic monoclonal antibodies for treatment of melanoma |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5264557A (en) | 1991-08-23 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Polypeptide of a human cripto-related gene, CR-3 |
| US6063379A (en) | 1993-12-09 | 2000-05-16 | Centro De Inmunologia Molecular | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies |
| US5981215A (en) * | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
| JP4124486B2 (ja) * | 1996-05-22 | 2008-07-23 | ビベンティア バイオテック インコーポレイテッド | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 |
| IL125608A0 (en) | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| SI2112166T1 (sl) | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Človeška monoklonska protitelesa proti CTLA-4 |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| DK1167537T3 (da) | 1999-03-30 | 2008-11-10 | Japan Tobacco Inc | Fremgangsmåde til fremstilling af et monoklonalt antistof |
| AU4648900A (en) * | 1999-04-20 | 2000-11-02 | William J. Kokolus | Improved method of identifying and locating immunobiologically-active linear peptides |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| JP2001046066A (ja) | 1999-08-03 | 2001-02-20 | Kyowa Hakko Kogyo Co Ltd | 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体 |
| WO2001040309A2 (en) | 1999-10-29 | 2001-06-07 | Genentech, Inc. | Anti-prostate stem cell antigen (psca) antibody compositions and methods of use |
| US6663613B1 (en) | 2000-01-25 | 2003-12-16 | Bacchus Vascular, Inc. | System and methods for clot dissolution |
| AU2001236073B2 (en) | 2000-03-03 | 2006-10-19 | Kyowa Kirin Co., Ltd. | Gene recombinant antibody and its fragment |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0020953D0 (en) | 2000-08-24 | 2000-10-11 | Smithkline Beecham Biolog | Vaccine |
| AU2001292724B2 (en) | 2000-09-18 | 2005-05-26 | Biogen Idec Ma Inc. | CRIPTO mutant and uses thereof |
| WO2002059620A2 (en) | 2001-01-26 | 2002-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Detection and quantification of cripto-1 |
| PL372140A1 (en) | 2001-01-29 | 2005-07-11 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
| US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
| AUPR395801A0 (en) | 2001-03-26 | 2001-04-26 | Austin Research Institute, The | Antibodies against cancer |
| AU2002334799B2 (en) * | 2001-04-26 | 2009-05-07 | Biogen Ma Inc. | Cripto-specific antibodies |
| US7582299B2 (en) * | 2001-04-26 | 2009-09-01 | Biogen Idec Ma Inc. | Cripto-specific antibodies |
| MXPA03009797A (es) | 2001-04-26 | 2004-01-29 | Biogen Inc | ANTICUERPOS PARA BLOQUEO DE PROTEiNA CRIPTO Y USO DE LOS MISMOS. |
| JP2005536439A (ja) * | 2001-09-18 | 2005-12-02 | ジェネンテック・インコーポレーテッド | 腫瘍の診断及び治療のための組成物と方法 |
| US20040014690A1 (en) * | 2002-02-13 | 2004-01-22 | Zhenkun Ma | Macrolides with activity against methicillin-resistant staphylococcus aureus |
| ATE437950T1 (de) * | 2003-09-15 | 2009-08-15 | Res Dev Foundation | Cripto-antagonismus von activin und tgf-b signalisierung |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| CA2650379A1 (en) | 2006-04-28 | 2007-11-08 | Biogen Idec Ma Inc. | Composition and methods for the detection of cripto-3 |
-
2002
- 2002-04-17 MX MXPA03009797A patent/MXPA03009797A/es active IP Right Grant
- 2002-04-17 EP EP02731384A patent/EP1390389B1/en not_active Expired - Lifetime
- 2002-04-17 JP JP2002585468A patent/JP4307845B2/ja not_active Expired - Fee Related
- 2002-04-17 CA CA2443840A patent/CA2443840C/en not_active Expired - Fee Related
- 2002-04-17 EE EEP200300528A patent/EE200300528A/xx unknown
- 2002-04-17 SK SK1443-2003A patent/SK14432003A3/sk not_active Application Discontinuation
- 2002-04-17 DK DK02731384T patent/DK1390389T3/da active
- 2002-04-17 CN CNB028128877A patent/CN100352501C/zh not_active Expired - Fee Related
- 2002-04-17 EP EP10186149A patent/EP2316486A3/en not_active Withdrawn
- 2002-04-17 WO PCT/US2002/011950 patent/WO2002088170A2/en not_active Ceased
- 2002-04-17 SG SG200600551-6A patent/SG157951A1/en unknown
- 2002-04-17 PT PT02731384T patent/PT1390389E/pt unknown
- 2002-04-17 SI SI200230804T patent/SI1390389T1/sl unknown
- 2002-04-17 CZ CZ20033208A patent/CZ20033208A3/cs unknown
- 2002-04-17 EA EA200301158A patent/EA007469B1/ru not_active IP Right Cessation
- 2002-04-17 KR KR1020037014078A patent/KR100592357B1/ko not_active Expired - Fee Related
- 2002-04-17 NZ NZ566268A patent/NZ566268A/en not_active IP Right Cessation
- 2002-04-17 BR BRPI0209254-9A patent/BR0209254A/pt not_active IP Right Cessation
- 2002-04-17 RS YU84903A patent/RS51635B/sr unknown
- 2002-04-17 TR TR2003/01846T patent/TR200301846T2/xx unknown
- 2002-04-17 HU HU0501113A patent/HUP0501113A3/hu unknown
- 2002-04-17 EP EP08158456A patent/EP1974749B1/en not_active Expired - Lifetime
- 2002-04-17 CA CA2715570A patent/CA2715570A1/en not_active Abandoned
- 2002-04-17 GE GE5415A patent/GEP20074091B/en unknown
- 2002-04-17 DE DE60230868T patent/DE60230868D1/de not_active Expired - Lifetime
- 2002-04-17 AT AT02731384T patent/ATE420659T1/de active
- 2002-04-17 AT AT08158456T patent/ATE533508T1/de active
- 2002-04-17 PL PL373513A patent/PL207087B1/pl unknown
- 2002-04-17 RS RS20110024A patent/RS20110024A/sr unknown
- 2002-04-17 ES ES02731384T patent/ES2321065T3/es not_active Expired - Lifetime
- 2002-04-23 MY MYPI2010003173A patent/MY150237A/en unknown
- 2002-04-23 MY MYPI20021484A patent/MY157382A/en unknown
- 2002-04-24 AR ARP020101492A patent/AR037223A1/es active IP Right Grant
-
2003
- 2003-10-23 US US10/693,538 patent/US7531174B2/en not_active Expired - Lifetime
- 2003-10-24 IS IS6999A patent/IS2662B/is unknown
- 2003-10-27 NO NO20034805A patent/NO20034805L/no not_active Application Discontinuation
- 2003-11-14 BG BG108363A patent/BG108363A/bg unknown
-
2005
- 2005-07-11 JP JP2005202361A patent/JP2005314436A/ja active Pending
-
2007
- 2007-04-30 US US11/799,361 patent/US7674462B2/en not_active Expired - Lifetime
-
2008
- 2008-12-22 US US12/317,476 patent/US8003763B2/en not_active Expired - Lifetime
-
2009
- 2009-01-14 US US12/353,913 patent/US20090285818A1/en not_active Abandoned
- 2009-02-05 JP JP2009025420A patent/JP4575983B2/ja not_active Expired - Fee Related
- 2009-03-31 US US12/415,659 patent/US7888052B2/en not_active Expired - Lifetime
- 2009-04-08 CY CY20091100413T patent/CY1108960T1/el unknown
- 2009-07-08 AR ARP090102597A patent/AR072554A2/es not_active Application Discontinuation
- 2009-12-22 CL CL2009002199A patent/CL2009002199A1/es unknown
-
2010
- 2010-02-15 JP JP2010030683A patent/JP2010163438A/ja not_active Withdrawn
- 2010-07-16 AR ARP100102604A patent/AR077759A2/es not_active Application Discontinuation
-
2011
- 2011-08-19 US US13/213,499 patent/US8673303B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS6999A (is) | Mótefni sem blokka prótínið Cripto og notkun þeirra | |
| EP1412378A4 (en) | APTAMERES AND ANTIAPTAMERS | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| FI20010157L (fi) | Probioottiyhdistelmä | |
| EP1298180A4 (en) | HYDROPHOBIC AND LIPOPHOBE COMPOSITION | |
| DE60212600D1 (de) | Audiocodierung und decodierung | |
| NO20033418L (no) | Immunregulatoriske antistoffer og anvendelse derav | |
| DE60238894D1 (de) | Beleuchtungssystem und dessen Verwendung in Projektionssystem | |
| IS6779A (is) | Mannlíkt mótefni gegn LT-beta-R | |
| DK1746375T3 (da) | Oxygendrevet forbrændingssystem og anvendelser deraf | |
| EP1423120A4 (en) | 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF | |
| NO20034159L (no) | Östrogen-gestagen-kombinasjonspreparat og anvendelse derav | |
| ITRM20020264A0 (it) | Articolo assorbente e procedimento per la sua fabbricazione. | |
| FI20010694A0 (fi) | Implantti | |
| EP1375518A4 (en) | ANTIBODIES AGAINST OST OPONTINE, AND ITS USE | |
| DE60220486D1 (de) | Zurückschaltungseinrichtung und Zurückschaltungsverfahren | |
| EP1351388A4 (en) | PHASE SLIDER AND MULTIBIT PHASE SLIDER | |
| DE60223675D1 (de) | Homogenisiervorrichtung | |
| DE60144265D1 (de) | Halbleiterbauelement und dessen herstelllung | |
| NO20041219L (no) | Manipulersikkert festeband | |
| DE60203475D1 (de) | Drosselklappe und Drossel | |
| AU2002357934A8 (en) | Humanized lactoferrin and uses thereof | |
| DE60205008D1 (de) | Kettelverfahren und -vorrichtung | |
| IS8914A (is) | Mótefni sem blokka prótínið Cripto og notkun þeirra | |
| DE60219418T8 (de) | Silanylphenole und -naphthole |